Chaudhari, 2024 - Google Patents
Investigations on the Potential Role of Tripartite Motif 34 (TRIM34) Expression in Lung Cancer TumorigenesisChaudhari, 2024
- Document ID
- 216154445513745439
- Author
- Chaudhari K
- Publication year
- Publication venue
- PQDT-Global
External Links
Snippet
Cancer is a complex and multifaceted disease characterized by the uncontrolled growth and spread of abnormal cells in body. It is the second leading cause of death globally, demanding extensive scientific research for improved understanding and therapeutic …
- 230000014509 gene expression 0 title abstract description 24
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cocco et al. | Biomarkers in triple-negative breast cancer: state-of-the-art and future perspectives | |
Zhang et al. | Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma | |
Ambrogio et al. | Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma | |
Tsvetkov et al. | Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome | |
Poon et al. | Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma | |
Yang et al. | DNA-sensing and nuclease gene expressions as markers for colorectal cancer progression | |
Angulo et al. | The role of epigenetics in the progression of clear cell renal cell carcinoma and the basis for future epigenetic treatments | |
US20180306796A1 (en) | Methods and compositions relating to proteasome inhibitor resistance | |
WO2015089338A9 (en) | Glucocorticoid inhibitors for treatment of prostate cancer | |
Liddiard et al. | DNA Ligase 1 is an essential mediator of sister chromatid telomere fusions in G2 cell cycle phase | |
Elsayed et al. | Back to the future: rethinking the great potential of lncRNAS for optimizing chemotherapeutic response in ovarian cancer | |
US20180353445A1 (en) | Methods and compositions relating to proteasome inhibitor resistance | |
Schumann et al. | Deficiency for SAMHD1 activates MDA5 in a cGAS/STING-dependent manner | |
Lee et al. | Genome‐scale CRISPR screening identifies cell cycle and protein ubiquitination processes as druggable targets for erlotinib‐resistant lung cancer | |
Xiang et al. | A Ubiquitin‐Dependent Switch on MEF2D Senses Pro‐Metastatic Niche Signals to Facilitate Intrahepatic Metastasis of Liver Cancer | |
Misek et al. | Ibrutinib blocks YAP1 activation and reverses BRAF inhibitor resistance in melanoma cells | |
Danisik et al. | Identification of collateral sensitivity and evolutionary landscape of chemotherapy-induced drug resistance using cellular barcoding technology | |
Chaudhari et al. | Investigations on the Potential Role of Tripartite Motif 34 (TRIM34) Gene Expression in Lung Cancer Tumorigenesis | |
Martins et al. | A Cluster of Evolutionarily Recent KRAB Zinc Finger Proteins Protects Cancer Cells from Replicative Stress–Induced Inflammation | |
Bhin et al. | MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer | |
Meira et al. | Prognostic Factors and Markers in Non-Small Cell Lung Cancer: Recent Progress and Future Challenges | |
Wu et al. | Identification of specific prognostic markers for lung squamous cell carcinoma based on tumor progression, immune infiltration, and stem index | |
Deeg et al. | Dissecting telomere maintenance mechanisms in pediatric glioblastoma | |
Awad et al. | Integrated drug profiling and CRISPR screening identify BCR:: ABL1-independent vulnerabilities in chronic myeloid leukemia | |
Ge et al. | A multiomics approach reveals RNA dynamics promote cellular sensitivity to DNA hypomethylation |